From 19th century ‘white blood’ observations and pathological anatomy to the discovery of BCR-ABL and imatinib, leukemia care ...
Despite a host of checks and balances that usually prevent harmful genetic mutations, sometimes mistakes happen, with serious ...
HLF-positive B cell acute lymphoblastic leukemia (B-ALL) sits among the most aggressive blood cancers seen in children. The ...
Day-28 complete response occurred in 54/78 B-ALL patients, with MRD negativity in 83.3% of responders and median OS 13.6 ...
March 24 (Reuters) - Pharmaceutical company Merck is nearing a roughly $6 billion all-cash deal to acquire biotech firm Terns ...
Merck & Co. Inc. MRK is nearing an all-cash deal to acquire Terns Pharmaceuticals, Inc. TERN for roughly $6 billion, aiming ...
A Round for Regan was first organized in August of 2024 to support Paul and Emily Tremain, and their daughter, Regan, following her diagnosis of B-Cell Acute Lymphoblastic Leukemia. The golf outing ...
2h
Merck buying Terns in $6.7B deal to bolster its cancer portfolio before key Keytruda patent expires
Merck is buying oncology company Terns Pharmaceuticals in a deal valued at approximately $6.7 billion as the pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results